Cancer Immunotherapy

8:30

8:30

9:00

9:00

Supercharging the Tumor Microenvironment with the Engineered Cytokines NKTR-214 and NKTR-255

Ute Hoch

Executive Director, Clinical Pharmacology

Nektar Therapeutics

Approaches to modulate T and NK cells in hematologic malignancies

Natalie Bezman

Director, Immuno-Oncology Discovery

Bristol-Myers Squibb

11:30

Allogene: Leading the Next Revolution in Cell Therapy

Cyril Konto

Vice President, Clinical Development

Allogene Therapeutics

12:00

12:15

Targeting the Immune Inhibitory Receptor LILRB4 to Treat Acute Myeloid Leukemia

An Song

Senior Vice President, Development Sciences

Immune-Onc Therapeutics

12:45

CAR-TCR Therapies

2:00

Novel T cell engaging bispecific antibodies for cancer immunotherapy

Thomas Tan
Vice President, Immunology

Elstar Therapeutics

2:30

Off-the-Shelf Cell-based Cancer Immunotherapy: An iPSC Product Platform for Mass Production of Allogeneic CAR-T cell Products

Chia-Wei Chang

Scientist

Fate Therapeutics

3:00

Novel Anti-BMCA CAR-T Cells

Matthew Spear

Chief Medical Officer

Poseida Inc.

4:00

Antibody-TCR (AbTCR) T-cell therapy for solid and hematological malignancies

Jingyi Xiang

Director of Scientific Alliances

Eureka Therapeutics